Investigational drug · Phase 2
FL115
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Non-muscle Invasive Bladder Cancer (NMIBC).
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "FL115"
First trial start
2024
Aug 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FL115", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Non-muscle Invasive Bladder Cancer (NMIBC)
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "FL115" as an intervention, largest first.
Suzhou Forlong Biotechnology Co., LtdIndustry
NCT07131202 · 130 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 5, 2026
Drug: FL115+PD-1 · For: Advanced Solid Tumors
Sites: Guangzhou, China
- A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder CancerRecruiting
Suzhou Forlong Biotechnology Co., LtdIndustry
NCT07122414 · 80 participants (planned) · Start Aug 16, 2024 · Primary completion Oct 10, 2027
Drug: FL115; FL115+BCG · For: Non-muscle Invasive Bladder Cancer (NMIBC)
Sites: Beijing, China; Fuzhou, China; Wenzhou, China · 12 sites in all
- A Study of FL115 Monotherapy in Unresectable or Metastatic Solid TumorsActive, not recruiting
Suzhou Forlong Biotechnology Co., LtdIndustry
NCT07131189 · 30 participants (planned) · Start May 30, 2024 · Primary completion Jun 1, 2026
Drug: FL115 · For: Locally Advanced/Metastatic Solid Tumors
Sites: Beijing, China; Guangzhou, China; Jinan, China
- A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid TumorsNot yet recruiting
Suzhou Forlong Biotechnology Co., LtdIndustry
NCT07785193 · 29 participants (planned) · Start Sep 2026 · Primary completion Sep 2027
Drug: FL115 · For: Advanced Solid Tumours
Sites: South Brisbane, Australia
Suzhou Forlong Biotechnology Co., LtdIndustry
NCT06130722 · 18 participants · Start Dec 30, 2023 · Primary completion Feb 15, 2025
Drug: FL115 · For: Locally Advanced/Metastatic Solid Tumors
Sites: Newport Beach, California; San Diego, California; Canton, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
Dessein AF, Stechly L, Jonckheere N, et al. · Cancer Res 2010
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.